SRX Global Inc. provided an update on ARMR Sciences, its portfolio company. ARMR Sciences is developing ARMR-100, a clinical-stage anti-fentanyl vaccine candidate.
The ongoing Phase 1/2 trial for ARMR-100 shows a favorable safety profile. The trial reported no serious adverse events. ARMR-100 successfully generated an anti-fentanyl immune response in human subjects.
ARMR Sciences secured a contract with the Department of War. This contract involves co-developing a generative AI platform. The platform aims to accelerate medical countermeasure development.
The FDA accepted ARMR Sciences into its Model-Informed Drug Development (MIDD) program. The program will facilitate discussions on the company's modeling and regulatory strategy.
SRX leadership views these developments as positive validation of its investment.